XML 44 R34.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Debt obligations (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2018
Schedule of Short-term Debt | Short-term debt:
|  | Weighted average interest rate as of March 31, 2018 |  | Maturity |  |  | March 31, 2018 |  |  | December 31, 2017 |
|  |  |  |  |  |  | (U.S. $ in millions) |
Term loan JPY 28.3 billion (5) |  | JPY LIBOR+0.25% |  |  | 2018 |  |  | $ | — |  |  | $ | 251 |
Convertible debentures |  | 0.25% |  |  | 2026 | * |  |  | 514 |  |  |  | 514 |
Other |  | 11.68% |  |  | 2018 |  |  |  | 2 |  |  |  | 1 |
Current maturities of long-term liabilities |  |  |  | 786 |  |  |  | 2,880 |
Total short term debt |  |  | $ | 1,302 |  |  | $ | 3,646 |
* | Net-share settlement feature exercisable at any time.
Schedule of Senior Notes and Loans | Long-term debt includes the following:
|  | Weighted average interest rate as of March 31, 2018 |  | Maturity |  | March 31, 2018 |  |  | December 31, 2017 |
|  | % |  |  |  | (U.S. $ in millions) |
Senior notes EUR 1,750 million |  | 0.38% |  | 2020 |  | $ | 2,152 |  |  | $ | 2,095 |
Senior notes EUR 1,500 million |  | 1.13% |  | 2024 |  |  | 1,837 |  |  |  | 1,788 |
Senior notes EUR 1,300 million |  | 1.25% |  | 2023 |  |  | 1,593 |  |  |  | 1,550 |
Senior notes EUR 1,000 million (3) |  | 2.88% |  | 2019 |  |  | — |  |  |  | 1,199 |
Senior notes EUR 900 million (1) |  | 4.50% |  | 2025 |  |  | 1,109 |  |  |  | — |
Senior notes EUR 750 million |  | 1.63% |  | 2028 |  |  | 915 |  |  |  | 891 |
Senior notes EUR 700 million (1) |  | 3.25% |  | 2022 |  |  | 863 |  |  |  | — |
Senior notes EUR 700 million |  | 1.88% |  | 2027 |  |  | 859 |  |  |  | 837 |
Senior notes USD 3,500 million |  | 3.15% |  | 2026 |  |  | 3,492 |  |  |  | 3,492 |
Senior notes USD 3,000 million |  | 2.20% |  | 2021 |  |  | 2,997 |  |  |  | 2,996 |
Senior notes USD 3,000 million |  | 2.80% |  | 2023 |  |  | 2,992 |  |  |  | 2,992 |
Senior notes USD 2,000 million |  | 1.70% |  | 2019 |  |  | 2,000 |  |  |  | 2,000 |
Senior notes USD 2,000 million |  | 4.10% |  | 2046 |  |  | 1,984 |  |  |  | 1,984 |
Senior notes USD 1,500 million (3) |  | 1.40% |  | 2018 |  |  | — |  |  |  | 1,500 |
Senior notes USD 1250 million (2) |  | 6.00% |  | 2024 |  |  | 1,250 |  |  |  | — |
Senior notes USD 1250 million (2) |  | 6.75% |  | 2028 |  |  | 1,250 |  |  |  | — |
Senior notes USD 844 million |  | 2.95% |  | 2022 |  |  | 863 |  |  |  | 864 |
Senior notes USD 789 million |  | 6.15% |  | 2036 |  |  | 781 |  |  |  | 781 |
Senior notes USD 700 million |  | 2.25% |  | 2020 |  |  | 700 |  |  |  | 700 |
Senior notes USD 613 million |  | 3.65% |  | 2021 |  |  | 623 |  |  |  | 624 |
Senior notes USD 588 million |  | 3.65% |  | 2021 |  |  | 587 |  |  |  | 587 |
Senior notes CHF 450 million |  | 1.50% |  | 2018 |  |  | 472 |  |  |  | 461 |
Senior notes CHF 350 million |  | 0.50% |  | 2022 |  |  | 367 |  |  |  | 360 |
Senior notes CHF 350 million |  | 1.00% |  | 2025 |  |  | 368 |  |  |  | 360 |
Senior notes CHF 300 million |  | 0.13% |  | 2018 |  |  | 314 |  |  |  | 308 |
Fair value hedge accounting adjustments |  |  | (16 | ) |  |  | (2 | )
Total senior notes |  |  | 30,352 |  |  |  | 28,367 |
Term loan USD 2.5 billion (4) |  | LIBOR +1.1375% |  | 2018 |  |  | — |  |  |  | 285 |
Term loan USD 2.5 billion (4) |  | LIBOR +1.50% |  | 2017-2020 |  |  | — |  |  |  | 2,000 |
Term loan JPY 58.5 billion (5) |  | JPY LIBOR +0.55% |  | 2022 |  |  | — |  |  |  | 519 |
Term loan JPY 35 billion (6) |  | 1.42% |  | 2019 |  |  | — |  |  |  | 311 |
Term loan JPY 35 billion (6) |  | JPY LIBOR +0.3% |  | 2018 |  |  | — |  |  |  | 311 |
Total loans |  |  | — |  |  |  | 3,426 |
Debentures USD 15 million (7) |  | 7.20% |  | 2018 |  |  | — |  |  |  | 15 |
Other |  | 7.31% |  | 2026 |  |  | 5 |  |  |  | 5 |
Total debentures and others |  |  | 5 |  |  |  | 20 |
Less current maturities |  |  | (786 | ) |  |  | (2,880 | )
Derivative instruments |  |  | 16 |  |  |  | 2 |
Less debt issuance costs |  |  | (137 | ) |  |  | (106 | )
Total long-term debt |  | $ | 29,450 |  |  | $ | 28,829 |
Debt development
(1) | In March 2018, Teva Pharmaceutical Finance Netherlands II B.V., a Teva finance subsidiary, issued senior notes in an aggregate principal amount of €1.6 billion.
(2) | In March 2018, Teva Pharmaceutical Finance Netherlands III B.V., a Teva finance subsidiary, issued senior notes in an aggregate principal amount of $2.5 billion.
(3) | In March 2018, Teva redeemed in full its $1.5 billion 1.4% senior notes due in July 2018 and its €1.0 billion 2.88% senior notes due in April 2019.
(4) | During the first quarter of 2018, Teva prepaid approximately $2.3 billion principal amount of the remaining term loan facilities.
(5) | During the first quarter of 2018, Teva prepaid in full JPY 86.8 billion principal amount of the outstanding term loan facilities of which JPY 28.3 billion were in short-term debt as of December 31, 2017.
(6) | During the first quarter of 2018, Teva prepaid in full JPY 70 billion of its 1.42% and JPY LIBOR+0.3% outstanding term loans.
(7) | During the first quarter of 2018, Teva prepaid in full $15 million of its outstanding debentures.

X
- Definition A schedule of data and information pertaining to long-debt instruments or arrangements, excluding convertible debt, that includes identification, terms, features, collateral requirements and other information necessary to a fair presentation. + References No definition available. + Details
Name: | teva_LongTermDebtExcludingConvertibleDebtTableTextBlock
Namespace Prefix: | teva_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_ScheduleOfShortTermDebtTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration